Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Acquisitions & Divestments (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with $86.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 19.48% to $86.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $337.9 million, a 4.94% decrease, with the full-year FY2025 number at $337.9 million, down 4.94% from a year prior.
  • Change in Acquisitions & Divestments was $86.9 million for Q4 2025 at Pliant Therapeutics, up from $80.3 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $152.8 million in Q3 2023 to a low of $33.8 million in Q3 2022.
  • A 5-year average of $81.2 million and a median of $79.3 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 55.36% in 2022, then surged 352.17% in 2023.
  • Pliant Therapeutics' Change in Acquisitions & Divestments stood at $64.3 million in 2021, then fell by 12.12% to $56.5 million in 2022, then soared by 58.36% to $89.5 million in 2023, then decreased by 18.76% to $72.7 million in 2024, then increased by 19.48% to $86.9 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Change in Acquisitions & Divestments are $86.9 million (Q4 2025), $80.3 million (Q3 2025), and $87.2 million (Q2 2025).